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Abstract
Background:  Mutations in the haemoglobin beta-globin (HbB)  and glucose-6-phosphate
dehydrogenase (G6PD) genes cause widespread human genetic disorders such as sickle cell diseases
and G6PD deficiency. In sub-Saharan Africa, a few predominant polymorphic variants of each gene
account for a majority of these deficiencies. Examining at a larger scale the clinical importance of
these independent genetic disorders, their possible association with malaria pathogenesis and
innate resistance, and their relevance for antimalarial drug treatment, would be easier if an accurate
screening method with limited costs was available.
Methods: A simple and rapid technique was developed to detect the most prominent single
nucleotide polymorphisms (SNPs) in the HbB and G6PD genes. The method is able to detect the
different haemoglobin polymorphisms A, S, C and E, as well as G6PD polymorphisms B, A and A-
based on PCR-amplification followed by a hybridization step using sequence-specific
oligonucleotide probes (SSOPs) specific for the SNP variants and quantified by ELISA.
Results: The SSOP-ELISA method was found to be specific, and compared well to the commonly
used PCR-RFLP technique. Identical results were obtained in 98% (haemoglobin) and 95% (G6PD)
of the tested 90 field samples from a high-transmission area in Tanzania, which were used to
validate the new technique.
Conclusion: The simplicity and accuracy of the new methodology makes it suitable for application
in settings where resources are limited. It would serve as a valuable tool for research purposes by
monitoring genotype frequencies in relation to disease epidemiology.
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Background
Sickle cell disease and glucose-6-phosphate dehydroge-
nase (G6PD) deficiency are widespread inherited, but
independent, human genetic disorders affecting millions
of people [1-3]. Whereas G6PD deficiency is an x-linked
enzymopathy and among the most common genetic dis-
order in humans [3], sickle cell disease is a common and
severe haemoglobinopathy, caused by sickling haemo-
globin [2]. The cytoplasmic G6PD enzyme is expressed in
all tissues and is essential for the capacity of cells to with-
stand oxidative stress. Individuals with lowered levels of
the G6PD enzyme are more susceptible to develop acute
haemolytic anaemia [4]. Apart from childhood death,
patients with sickle cell diseases suffer from diverse clini-
cal conditions including anaemia, infarctions and other
variable painful crisis throughout life [5].
The disorders arise from single nucleotide point muta-
tions in the haemoglobin beta-globin (HbB) and glucose-
6-phosphate dehydrogenase (G6PD) genes, resulting in
single amino acid substitutions. Despite the fact that more
than hundred allelic variants have been described for each
polymorph gene-locus, only a few reach high frequencies
and, thus, become of clinical importance [1,3].
In sub-Saharan Africa, G6PD is essentially a tri-allelic pol-
ymorphism. G6PD (B) is the most common allele with
normal enzymatic activity; G6PD (A) is associated with a
single amino acid substitution at codon (c) 126 where Asn
is changed to Asp (N126D), causing around 85% of the
normal enzymatic activity. The G6PD (A-) deficiency
allele has a single amino acid substitution at c68 from Val
to Met (V68M), always in conjunction with the N126D
mutation [6]. The G6PD (A-) variant has only around
12% of normal enzymatic activity with frequencies of 5–
25% of the affected population in sub-Saharan Africa [7].
Although most individuals with the G6PD (A-) polymor-
phic variant are asymptomatic, acute haemolytic anaemia
can manifest in hetero- and homozyogte females as well
as hemizygote males under oxidative stress of the red
blood cells [7]. This condition can be induced by infec-
tions, anti-inflammatory agents and chemotherapeutics,
including anti-malarials such as sulphadoxine-pyrimeth-
amine, lapudrine-dapsone or primaquine, making it of
importance to know the G6PD status of individuals
receiving drug treatment [4].
The most prevalent polymorphic variants of the HbB gene
consist of the normal gene (HbA) in which SNPs in the
same amino acid position give rise to either the sickle hae-
moglobin S, (HbS, Glu to Val at c6 (E6V)) or the common
west-African haemoglobin C (HbC, Glu to Lys at c6
(E6K)). A third SNP at position 26 creates the Southeast-
Asian haemoglobin E (HbE, Glu to Lys (E26K)) variant,
which is not found in Africa [1]. Apart from several other
abnormal haemoglobin gene-combinations, such as beta-
thalassaemia, sickle cell disease is found in individuals
with homozygote HbSS (sickle cell anaemia) and hetero-
zygote SC genotypes, whereas the inheritance of two C-
alleles (HbCC) or one A plus one C or S allele (HbAS and
HbAC) give rise to phenotypes associated with limited
pathology [1]. Both haemoglobin S, C and E confer some
degree of protection against severe malaria [8-10]. In sub-
Saharan Africa, HbS gene frequencies exceed 25%, result-
ing in a widespread, but unequal distribution of the HbAS
sickle cell trait [2].
The procedures for diagnosing sickle cell anaemia and
G6PD deficiency includes the sickling test, haemoglobin
electrophoresis [1,11] and enzymatic diagnostic assay
[13]. Current approaches also deploy DNA-analysis using
PCR-restriction fragment length polymorphism (RFLP)
[9,14-16], allele-specific oligonucleotide hybridization
[10,17] or dot-blot hybridization analysis of the appropri-
ate PCR-amplified fragments [18]. However, these tech-
niques can have difficulties in detecting heterozygotes and
discerning false-negatives and false-positives thereby
hampering specificity and sensitivity [19]. Furthermore,
the methods are relatively laborious, technically demand-
ing and expensive, and may, therefore, be inappropriate
for screening large numbers of samples in resource-poor
settings.
Here, a method for screening human populations for the
different haemoglobin polymorphisms A, S, C and E as
well as the G6PD polymorphisms B, A and A- by use of
PCR and sequence-specific oligonucleotide probes
(SSOPs) to detect the various SNPs and visualized in an
ELISA system, is described and evaluated. The methodol-
ogy is accurate and simple and would be applicable at lab-
oratories with limited facilities.
Methods
Samples and DNA-extraction
Blood samples from 90 children under the age of five
years, living in Mkokola village in North-Eastern Tanza-
nia, collected on filter paper during a cross-sectional sur-
vey in March 2004, were used for validation of the
method. Informed consent was obtained from parents or
guardians of the study participants and the study protocol
was ethically approved by the Tanzanian National Insti-
tute of Medical Research.
DNA samples of two donors with HbCC and HbAS geno-
types and two donors with G6PD (A-), genotypes 68 MM
(homozygote for 68 mutation) and G6PD (A), genotype
68VM/126ND (heterozygote for both mutations), respec-
tively, served as positive controls. DNA extracted from vol-
unteering Danish blood donors were used as controls for
wildtype HbAA and G6PD (B) (68VV/126NN). Two sam-Malaria Journal 2005, 4:61 http://www.malariajournal.com/content/4/1/61
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ples from the villages Kwemasimba and Tamota in neigh-
bouring areas were identified by the RFLP technique to be
HbSS-type and HbAC-type, respectively, and were used as
controls in comparison with the SSOP-ELISA technique.
DNA was extracted from segments of bloodspots on filter
paper in 96-well plate format by a Chelex-100 method
described previously [20].
PCR conditions
Primers, as described in Mombo et al. [16], were used to
amplify a 919 bp fragment of the G6PD gene covering the
two mutation sites at codon 68 and 126. The HbB gene
was amplified by primers as described in Modiano et al.
[9] to produce a 358 bp fragment covering the mutation
sites at codon 6 and 26. Both reverse primers were bioti-
nylated at the 5'-end by the supplier (MWG Biotech, Eber-
sberg, Germany).
One µl of DNA-extracted samples were amplified in 20 µl
of PCR reaction mixture consisting of 0.2 mM of each
dNTP, 2 µM of each primer-set, 1 unit of DNA Qiagen
HotStart polymerase (Qiagen, Albertslund, Denmark),
Qiagen buffer containing 2.5 mM MgCl2.
The PCR conditions for both the G6PD and HbB gene
were 15 minutes of incubation at 94°C, followed by 45
amplification cycles of denaturation at 94°C for 30 sec-
onds, annealing at 60°C for 30 seconds and elongation at
72°C for 90 seconds (60 seconds for the HbB  gene),
before the final elongation at 72°C for 10 minutes. The
reactions were performed in 96-well PCR plates on a DNA
thermal cycler (MJ Research, Albertslund, Denmark). A
fraction of the PCR products were visualized by electro-
phoresis on a 1,5% agarose gel for 30 minutes for confor-
mation of the amplification.
Detection methods
SSOP-ELISA
Oligonucleotide-probes of 18 bases covering the muta-
tion sites were designed and 3'-end conjugated with dig-
oxigenin (MWG Biotech, Ebersberg, Germany) (Table 1).
The detection of the SNPs were performed according to
[21], with slight modifications. In brief, the amplified
PCR products were diluted 1:2 in dH20, denatured at
95°C for 5 minutes and kept at 4°C until use. 2 µl of the
PCR products, conjugated with biotin, were added to
streptavidin-coated (1 µg/ml PBS) ELISA plates (Max-
isorp; Nunc, Roskilde, Denmark) containing 100 µl PBS
with 0.05% Tween-20 and incubated for one hour at
room temperature. The bound PCR-products were incu-
bated with 8 nM of either probe in tetra-methyl ammo-
nium chloride (TMAC; Sigma Aldrich, Seelze, Germany)
solution (3 M TMAC, 50 mM Tris, pH 8.0, 0.1 sodium
dodecyl sulfate, 2 mM EDTA, pH 8.0) at 53°C with shak-
ing for an hour, followed by 2 × 10 minutes. TMAC-wash-
ing at temperatures set to 62°C for the haemoglobin
probes and 65°C for the G6PD probes, respectively. The
plates were incubated with peroxidase-conjugated anti-
digoxigenin antibody (Roche Diagnostics, Mannheim,
Germany) 1:1000 in PBS with 0.05% Tween-20 at room
temperature for one hour, thereafter visualised by o-phe-
nylene-diamine (OPD) (Dako, Glostrup, Denmark). The
reaction was stopped with H2SO4, before measuring the
optical density (OD) at 492 nm. Between each step, the
ELISA plates were washed three times in PBS with 0.05%
Tween-20. As the OD values of positive and negative con-
Table 1: Sequences of the digoxigenin-conjugated sequence-specific oligonucleotide probes (SSOPs). The SSOP-ID named the 
sequences used in detection of the haemoglobin and G6PD single nucleotide polymorphisms (SNPs).
SSOP ID SSOP sequence1 Nucleotide substitution Amino acid substitution
HbB
HbA-6: 5' TGACTCCTGAGGAGAAGT
HbS-6: 5' TGACTCCTGTGGAGAAGT A18T E6V
HbC-6: 5' TGACTCCTAAGGAGAAGT G17A E6K
HbA-26 5' TTGGTGGTGAGGCCCTGG
HbE-26: 5' TTGGTGGTAAGGCCCTGG G77A E26K
G6PD
68V 5' CACCTTCATCGTGGGCTA
68M 5' CACCTTCATCATGGGCTA G202A V68M
126N 5' GCCACATGAATGCCCTCC
126D 5' GCCACATGGATGCCCTCC A376G N126D
1: Letters in bold indicate the nucleotide-substitutionsMalaria Journal 2005, 4:61 http://www.malariajournal.com/content/4/1/61
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Mean reactivity (OD value) and 95% confidence intervals in ELISA-SSOP assay of samples with known genotype Figure 1
Mean reactivity (OD value) and 95% confidence intervals in ELISA-SSOP assay of samples with known geno-
type. Panel a) shows genotyping results of the HbB gene (genotypes AA, AS, CC, AC, SS) using probes reacting with HbA, HbS 
and HbC, respectively. Panel b) and c) shows genotyping results for G6PD for samples from individuals with the indicated gen-
otypes using probes against 68V, 68M, 126N and 126D, respectively. All experiments were performed 4 times.Malaria Journal 2005, 4:61 http://www.malariajournal.com/content/4/1/61
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trols changed between experiments, probably due to dif-
ferences in strength of the probe binding, no fixed cut-off
value could be specified; thus, for each SNP test, assay-
specific cut-off values were defined.
Restriction fragment length polymorphism (RFLP)
In order to validate the method, comparative RFLP analy-
ses were performed on similar PCR products used for the
SSOP-ELISA technique. The 919 bp PCR fragment of the
G6PD gene was digested with restriction enzyme NlaIII,
which permits discrimination of the 68V and 68M geno-
types [16], and BsmI, which allows discrimination of the
126N and 126D genotypes. The 358 bp fragment of the
HbB gene was digested with restriction enzyme MnlI and
DdeI for discrimination of the different haemoglobin pol-
ymorphisms, according to [9]. All digestions were carried
out for a minimum of three hours, at 37°C for NlaIII,
DdeI and MnlI, and 65°C for BsmI according to manufac-
turer's instructions, and resolved on 2–2.5% metaphor
agarose gels (Medinova, Glostrup, Denmark).
Results
Specificity of the genotyping assay
In order to assess the capacity of the SSOP-ELISA tech-
nique to correctly detect HbB and G6PD SNPs, control
DNA samples from individuals with known HbAA,
HbCC, HbSS, HbAC and HbAS genotypes together with
G6PD (68VV/126NN), (68VM/126ND) and (68MM/
126DD) genotypes, were used to optimize the screening
method.
Using the control samples, all SSOPs identified with high
specificity the appropriate SNPs in the DNA. The differ-
ence in OD-values between the cut-off value and the pos-
itive reactions (∆-OD) was always higher than 2.0 for the
haemoglobin samples and higher than 1.5 for the G6PD
samples (Figure 1). A sample from an individual with the
HbE mutation was not available, and therefore it was not
possible to test the specificity of the HbE-26 probe. How-
ever, the probe HbA-26, specific for the normal genotype
at c26, recognized the all samples with OD values above
2.0 (data not shown). The reaction intensity was equally
strong in samples where each probe detected one allele
(heterozygote and hemizygote) or two identical alleles
(homozygote).
The procedure was optimized to different TMAC washing
temperatures for the different probes, reaching an opti-
mum specificity of 62°C and 65°C for HbB and G6PD
probes, respectively. However, with slight decrease in spe-
cificity, both assays could be performed using a TMAC
washing temperature in the range of 62–65°C. Although
weak results could be obtained by applying the probes
and PCR-products together at 53°C, saving one hour of
the duration of the procedure, the strongest and most spe-
cific results were obtained by separating the PCR-product
and probe incubations (one hour each). Similar, attempts
to combine the two amplifications in one PCR-reaction
(multiplex) also reduced the specificity and intensity of
both PCR products. The cheaper and less hazardous
tetramethylbenzidine (TMB) performed as well as OPD in
the detection step.
SSOP-ELISA versus the RFLP method
To test the SSOP-ELISA technique on samples from the
field, DNA was extracted from filter paper blood spots col-
lected from 90 children living in a Tanzanian village. The
assay was able to screen these samples for the three hae-
moglobin and two G6PD SNPs during one day and deter-
mine the genotype frequencies (Table 2). The majority of
the 90 samples were amplified by PCR, except three for
the HbB gene and six samples for the G6PD gene. Of the
PCR-amplified samples, the majority reacted with the
SSOPs with a signal-to-background OD value above 1.0.
As expected, no samples with HbC or HbE were identified
in the village. Twelve individuals carried one HbS allele
Table 2: HbB and G6PD genotype frequencies for children living in a Tanzanian village and analysed by the SSOP-ELISA method.
HbB Genotype Numbers (87)a G6PD Genotype Numbers (84)a 68 Status 126 Status Deduced 
Phenotypeb
68–126
AA 75 (86%) VV-NNc 51 (61%) Wildtype Wildtype G6PD B
SS 0 VV-DDd 8 (10%) Wildtype Mutant G6PD A
AS 12 (14%) M-De 6 (7%) Mutant Mutant G6PD A-
AC 0 VM-ND 10 (12%) Single Mutant Single Mutant G6PD A
CC 0 VV-ND 8 (9%) Wildtype Single Mutant G6PD A
SC 0 VM-DD 1 (1%) Single Mutant Mutant G6PD A
No PCR-product 3 No PCR-product 6
a: Numbers refer to the remaining individuals from the field with amplified PCR-product
b: Phenotype of the G6PD trait was not measured, but deduced based on the genotype
c: Out of the 51 individuals, 30 were males with the V-N genotype
d: Out of the 8 individuals, 5 were males with the V-D genotype
e: All 6 individuals were males hemizygote for M-D genotypeMalaria Journal 2005, 4:61 http://www.malariajournal.com/content/4/1/61
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and had the HbAS genotype, corresponding to a preva-
lence of 14% of the sickle cell trait. The majority the indi-
viduals, 86% (75/87), carried the normal HbAA genotype.
For G6PD, 61% (51/84) had the (68VV/126NN) normal
genotype (G6PD B variant), whereas 20% (17/84) had the
68M mutation. These individuals could be divided into 6
(7%) with the deficient genotype (68M/126D – only
hemizygote males), having the G6PD (A-) variant, and 11
(13%) which were heterozygote for the 68M mutation (10
with 68MV/126ND and 1 with 68MV/126DD) genotype
having the G6PD (A) variant.
To verify the genotypes determined by the SSOP-ELISA
assay, the PCR-products were processed by the RFLP
method, which currently is commonly used for genotyp-
ing. For HbB, control and field samples gave identical
results in 98% (88/90) of the cases. A minor disagreement
was found in two samples typed as AS and AC, respec-
tively. The samples had weak positive signals for the S and
C probes close to the cut-off OD value of 0.3 in the SSOP-
ELISA method. The restriction digestion analysis typed the
samples as HbAA and not AC or AS.
Among 87 samples amplified for G6PD, there was 95%
(83/87) and 97% (84/87) concordance between the two
methods for the 68 and 126 mutation, respectively. Four
samples with positive signals for 68V, showed weak sig-
nals with OD values between 0.2 and 0.5 for the 68M
probe. Two of these were typed as 68MV by the RFLP
method, whereas the two remaining were typed as 68VV.
Another three samples, initially considered containing the
126D allele, typed as either 126DN or 126NN by the RFLP
method. Ten samples (6 for the 68 mutation and 4 for the
126 mutation) with clear-cut OD values by the SSOP-
ELISA method were difficult to interpret by the RFLP
method due to ambiguous band-separation and band-res-
olution even after repeating the restriction digests. Com-
parisons of the results with the different methods are
shown in Table 3.
Discussion
To allow large-scale screening of clinically important
point mutations associated with G6PD deficiency and
haemoglobinopathies, to be applied in resource-poor set-
tings, a simple high-throughput SSOP-ELISA method was
developed as an alternative to the conventional RFLP-
method. Our new SSOP-ELISA method proved to be
highly accurate in detecting the different SNPs of both the
HbB and G6PD genes, with signal-to-background differ-
ences in OD values greater than 2.0 in most cases. Thus,
with only a minimum discordance between the results
obtained by the RFLP and SSOP-ELISA methods, the
SSOP-ELISA technique confirmed to be an efficient alter-
native to the RFLP method. Although the SSOP-ELISA
originally was developed for detecting Plasmodium falci-
parum haplotypes related to anti-malarial drug resistance,
the technique has been shown to be adapted to analyse
human genotypes as well. The results clearly showed that
the OD values were not reduced in samples with two dif-
ferent SNPs a (heterozygote) compared to samples with
two identical alleles (homozygotes). All individuals clas-
Table 3: Comparison of results obtained with the SSOP-ELISA (horizontal) and RFLP (vertical). The single nucleotide polymorphisms 
(SNPs) in the HbB gene (top) and G6PD gene (bottom) were targeted using DNA extracted from control samples and 90 individuals 
from the field.
HbB SSOP-ELISA
RFLP HbAA HbAS HbSS HbAC HbCC No PCR prod.
HbAA 74 1 1
HbAS 11
HbSS 1
HbAC 1
HbCC 1
No PCR-prod. 3
G6PD SSOP-ELISA
RFLP 68V 68M 68MV 126N 126D 126DN No PCR prod.
68V 64 2
68M 5
68MV 2 8
126N 50 1
126D 14
126ND 21 6
No PCR-prod. 6
Inconclusive 4 2 2 2Malaria Journal 2005, 4:61 http://www.malariajournal.com/content/4/1/61
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sified as heterozyogtes by the SSOP-ELISA were females,
as expected.
The chosen PCR-products have the advantage of covering
three important SNPs in the HbB gene and two important
SNPs in the G6PD gene. The single PCR product from the
G6PD gene covers both mutations, whereby amplification
of two fragments, as has been done previously, is avoided
[18,22]. The probes used were all designed to surround
the SNP in question and only in the case of the 68M SNP,
additional probes were designed to optimise a suitable
binding reaction. In contrast, the PCR-RFLP methodology
is dependent on recognisable restriction sites around the
SNP, limiting the choice of size of the PCR fragment and
binding of the primers. The SSOP-ELISA method also has
the advantage of not relying on laborious electrophoresis
work. Ambiguous results were more frequently observed
with the RFLP method, caused by either incomplete enzy-
matic digestion of PCR fragments or inaccurate gel-resolu-
tion and band separation. The generation of ELISA-based
OD values removes much of the conjecture over gel
results, and a simple spreadsheet can be used for data
analysis to identify samples, which need confirmation by
the RFLP method. With duration of approximately 3
hours for the PCR amplification step followed by 4 hours
for the SSOP-ELISA detection, 90 samples can easily be
screened for both haemoglobin and G6PD genotypes or
180 samples for either haemoglobin or G6PD, during one
day. Apart from being accurate and rapid, the technique is
also relatively cheap as costs pr. sample analyzed and
DNA extracted approximately is 1$.
From a practical point of view, setting up and running this
new method only requires the use of relatively cheap
equipment: a PCR thermal cycler, an incubation oven and
an ELISA reader. These are increasingly becoming com-
monplace in many settings, also in laboratories in
resource-poor settings in Africa. At this stage, the SSOP-
ELISA technique has already been established at sites in
Tanzania for the routine monitoring of molecular markers
of Plasmodium falciparum drug resistance. The method can
be adapted to other areas where different mutations pre-
dominate and even modified into a higher throughput
system with access to more advanced and expensive
equipment. In African populations, screening for the
V68M mutant only will suffice, if the intention is solely to
assess symptomatic G6PD deficiency [15,22].
The fact that this method is only able to detect specific
SNPs, limits its use to monitoring already known geno-
types, and sequencing analysis will be needed to identify
unknown molecular markers or other variants of G6PD
deficiency. Although by far the largest proportion of indi-
viduals with G6PD deficiency have the 68MM genotype,
making it unlikely that a person in sub-Saharan Africa
without the V68M mutation would be G6PD deficient
[12], it is important to consider that ethnically different
populations, e.g. with Arabic influence, could harbour
other G6PD deficient variants (e.g. the Arabic G6PDmed
variant) [12], and that rare deficiency mutations (G680T
and T968C) could be present [7].
Limited access to and delayed diagnosis of sickle cell dis-
eases and G6PD deficiency in tropical Africa may hamper
prevention of severe illness and consequently lead to
increases in morbidity and mortality [5]. Efficient high-
throughput screening methods, as described here, may
help to map the distribution of these inherited disorders
and, thus, contribute as an epidemiological tool to char-
acterize disease patterns. Molecular epidemiology of
genes promoting or protecting against disease, including
malaria, is important when large-scale interventions are
planned, e.g. studies on malaria immunity, vaccine trials
and drug trials.
Conclusion
Here, a simple screening method is described, detecting,
at molecular level and with limited costs, the most impor-
tant human haemoglobin and G6PD polymorphisms
associated with malaria. This assay represents a useful tool
for analysing the relation between various combinations
of these major genotypes and a variety of epidemiological
factors in particular malaria immunity, incidence and
severity. The method has proved to be accurate and rapid
and will be beneficial at research institutions in resource-
poor settings in Africa.
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